Efficacy and Safety of Bevacizumab Combined with Temozolomide in the Treatment of Glioma: A Systematic Review and Meta-Analysis of Clinical Trials

Glioma is the most common malignant brain tumor in neurosurgery. Bevacizumab (BEV) is a monoclonal antibody that inhibits tumors by inhibiting vascular endothelial growth factor and reducing tumor angiogenesis. To evaluate the efficacy and safety of BEV combined with temozolomide (TMZ) in glioma, we performed a meta-analysis.